Sign In

Ben Woodington

Co-founder of Opto.bio with expertise in bioelectronics and neural interfaces

Ben Woodington is the CEO and co-founder of Opto Biosystems, a bioelectronics start-up focused on developing minimally invasive neural interfaces aimed at treating neurological diseases. He has been in this role since May 2022, leading the company's mission to innovate in the field of neurotechnology and improve treatment options for challenging medical conditions such as brain cancer and epilepsy.123

Education and Background

Woodington completed his PhD in Bioelectronics at the University of Cambridge, where he specialized in developing flexible and shape-adaptive neural interfaces for sensing and stimulating the central nervous system.13 His academic journey also includes a Master of Research in Sensor Technologies and Applications and a Bachelor of Science in Chemistry from the University of Surrey.13

Before founding Opto Biosystems, he worked in various engineering and scientific roles, including positions at Vectura Group plc, where he contributed to the development and commercialization of medical devices.13 His experience in medical device engineering and bioelectronics research has been pivotal in translating his academic work into practical applications in healthcare.

Vision and Impact

Woodington's work at Opto aims to revolutionize how neurological diseases are treated by creating implantable, miniaturized sensors that can provide real-time monitoring of brain activity without the need for major surgery.23 The technology is designed to be less invasive, potentially allowing for outpatient procedures and improving patient outcomes in the treatment of serious conditions.23

Under his leadership, Opto Biosystems has garnered attention and funding, including £1.85 million in pre-seed funding to further develop its innovative technologies.24 Woodington's commitment to advancing bioelectronics reflects his belief in the transformative potential of technology in medicine, particularly in providing better tools for clinicians and improving patient care.3

Highlights

Jul 23 · linkedin

En route to NYC for this week's Decoding Bio AI x Bio event.

Looking forward to a packed 24hrs and, of course, sharing updates about Opto Biosystems' progress in cancer neurotechnology.

I'll be in NYC all week, give me a shout if you're in town and want to meet up.

May 16 · linkedin

Hello there,

Opto has two summer internship positions live.

If you're a budding neuroengineer or neural data scientist and want to spend an awesome summer with our UK-based Cambridge team. Get in touch and join us in building neurotechnology for cancer treatment.

Related Questions

What inspired Ben Woodington to co-found Opto Biosystems?
How does Ben Woodington's background in bioelectronics influence his leadership at Opto Biosystems?
What are the main challenges Ben Woodington faces as CEO of Opto Biosystems?
How does Opto Biosystems' technology compare to other neural interface technologies?
What are Ben Woodington's future plans for Opto Biosystems?
Ben Woodington
Ben Woodington, photo 1
Ben Woodington, photo 2
Add to my network

Experience

CEO + Co-Founder at Opto Biosystems since May 2022
PhD Candidate at University of Cambridge from October 2018 to February 2023, Lead Engineer - NPI at Vectura Group plc. from July 2018 to November 2018, Lead Scientist at Vectura Group plc. from May 20 at Philips from September 2012 to September 2013

Education

Doctor of Philosophy - PhD, Bioelectronics at University of Cambridge from 2019 to 2022, EnterpriseTECH Star Programme at Cambridge Judge Business School from 2019 to 2020, Distinction, EnterpriseTECH

Location

Greater Cambridge Area